arrow
A

Aynur Hermann

Regeneron
H指数:10
被引数:2,170

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Ra strengthens T cell-mediated anti-tumor therapies
2024-10-010
OAAI
REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy
2023-12-010
PRE
VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding
2023-06-212
OAAI
A PD-1-targeted, receptor-masked IL-2 immunocytokine with maintained potential to engage endogenous IL-2Ra drives selective stimulation of PD-1+ T cells and robust anti-tumor efficacy
2023-04-041
PRE
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models
2022-11-0924
PRE
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

通过CD3亲和力调节产生具有细胞因子释放和生物分布的分化特征的T细胞重定向双特异性抗体

2021-07-1364
OAAI
Selection of CD3 affinity allows generation of T-cell redirecting bispecific antibodies with unique pharmacokinetic and biodistribution properties
2020-08-151
PRE
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
2020-06-2466
PREAI
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

一类增强CD3-bispecific抗体抗肿瘤活性的共刺激CD28-bispecific抗体

2020-01-0894
OAAI
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Science
IF45.8
2020-01-010
OAAI
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice
2019-11-0164
OAAI
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
2017-05-02125
OAAI